TY - JOUR
T1 - Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells
AU - Salazar, Giulia
AU - Bellocchi, Chiara
AU - Todoerti, Katia
AU - Saporiti, Federica
AU - Piacentini, Luca
AU - Scorza, Raffaella
AU - Colombo, Gualtiero I.
PY - 2016/7/5
Y1 - 2016/7/5
N2 - Aminaphtone, a drug used in the treatment of chronic venous insufficiency (CVI), showed a remarkable role in the modulation of several vasoactive factors, like endothelin-1 and adhesion molecules. We analysed in vitro the effects of Aminaphtone on whole-genome gene expression and production of different inflammatory proteins. ECV-304 endothelial cells were stimulated with IL-1β 100 U/ml in the presence or absence of Aminaphtone 6 μg/ml. Gene expression profiles were compared at 1, 3, and 6 h after stimulation by microarray. Supernatants of ECV-304 cultures were analysed at 3, 6, 12, and 24 h by multiplex ELISA for production of several cytokine and chemokines. Microarrays showed a significant down-regulation at all times of a wide range of inflammatory genes. Aminaphtone appeared also able to modulate the regulation of immune response process (down-regulating cytokine biosynthesis, transcripts involved in lymphocyte differentiation and cell proliferation, and cytokine-cytokine receptor interaction) and to regulate genes engaged in homeostasis, secretion, body fluid levels, response to hypoxia, cell division, and cell-to-cell communication and signalling. Results were confirmed and extended analysing the secretome, which showed significant reduction of the release of 14 cytokines and chemokines. These effects are predicted to be mediated by interaction with different transcription factors. Aminaphtone was able to modulate the expression of inflammatory molecules relevant to the pathogenesis of several conditions in which the endothelial dysfunction is the main player and early event, like scleroderma, lung fibrosis, or atherosclerosis.
AB - Aminaphtone, a drug used in the treatment of chronic venous insufficiency (CVI), showed a remarkable role in the modulation of several vasoactive factors, like endothelin-1 and adhesion molecules. We analysed in vitro the effects of Aminaphtone on whole-genome gene expression and production of different inflammatory proteins. ECV-304 endothelial cells were stimulated with IL-1β 100 U/ml in the presence or absence of Aminaphtone 6 μg/ml. Gene expression profiles were compared at 1, 3, and 6 h after stimulation by microarray. Supernatants of ECV-304 cultures were analysed at 3, 6, 12, and 24 h by multiplex ELISA for production of several cytokine and chemokines. Microarrays showed a significant down-regulation at all times of a wide range of inflammatory genes. Aminaphtone appeared also able to modulate the regulation of immune response process (down-regulating cytokine biosynthesis, transcripts involved in lymphocyte differentiation and cell proliferation, and cytokine-cytokine receptor interaction) and to regulate genes engaged in homeostasis, secretion, body fluid levels, response to hypoxia, cell division, and cell-to-cell communication and signalling. Results were confirmed and extended analysing the secretome, which showed significant reduction of the release of 14 cytokines and chemokines. These effects are predicted to be mediated by interaction with different transcription factors. Aminaphtone was able to modulate the expression of inflammatory molecules relevant to the pathogenesis of several conditions in which the endothelial dysfunction is the main player and early event, like scleroderma, lung fibrosis, or atherosclerosis.
KW - Cytokines
KW - Endothelial cells
KW - Endothelin-1
KW - Gene expression profiling
KW - Inflammation
UR - http://www.scopus.com/inward/record.url?scp=84964687221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964687221&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2016.04.018
DO - 10.1016/j.ejphar.2016.04.018
M3 - Article
AN - SCOPUS:84964687221
VL - 782
SP - 59
EP - 69
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
ER -